Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas

Table 2

Comparison of laboratory indexes and BMI before and after treatment in 42 cases.

Group	Treatment time	ESR (mm/h)	CRP (mg/L)	BMI ()	ALB (g/L)
Conventional	Before treatment	31.78 ± 3.03	30.97 ± 6.86	17.66 ± 1.98	33.12 ± 1.61
	14 weeks after treatment	26.08 ± 2.89	10.87 ± 4.16	18.21 ± 2.09	37.88 ± 2.29
	30 weeks after treatment	14.24 ± 1.92	5.78 ± 2.59	19.98 ± 2.49	38.81 ± 2.69
IFX	Before treatment	36.43 ± 3.21	31.12 ± 6.99	17.52 ± 1.89	32.58 ± 1.67
	14 weeks after treatment	25.29 ± 2.92	12.35 ± 4.23	19.19 ± 2.13	38.92 ± 2.35
	30 weeks after treatment	13.21 ± 1.86	5.23 ± 2.63	20.26 ± 2.65	39.89 ± 2.72

Compared with that before treatment in the IFX treatment group: .
Compared with the IFX treatment group: .